Our perspectives
in one place
Topic
Selected filters
ClearNews
See all158th session of the WHO Executive Board: WHO’s work in health emergencies
We appreciate the opportunity to contribute to the discussions at EB158. WHO’s work on strengthening emergency preparedness reflects a shared commitment to ensuring the world is better equipped for future health threats. We welcome this direction and the emphasis on clarity, coordination, and readiness. As EB158 documents highlight, WHO will now take on an expanded set of responsibilities...
Read more158th session of the WHO Executive Board (EB158): Draft updated global action plan on antimicrobial resistance
On 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...
Read more158th session of the WHO Executive Board (EB158): Harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector
On 4 February 2026, IFPMA delivered a statement on Agenda item 15 on harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector at the 158th session of the WHO Executive Board in Geneva. Noting the work carried out by several multilateral institutions on digital health transformation,...
Read more158th session of the WHO Executive Board: Substandard and falsified medical products
On 4 February 2026, IAPO delivered a statement on Agenda item 12 on substandard and falsified medical products at the 158th session of the WHO Executive Board on behalf of the Fight the Fakes Alliance, of which IFPMA is a member. The International Alliance of Patients’ Organizations, on behalf of the Fight the Fakes Alliance,...
Read more158th session of the WHO Executive Board (EB158): Co-creating the Global Action Plan for rare diseases
On 3 February 2026, IFPMA delivered a statement on Agenda item 9: Co-creating the Global Action Plan for rare diseases at the 158th session of the WHO Executive Board. IFPMA commends Member States and the WHO for implementing the 2025 WHA Resolution on Rare Diseases and strongly supports the prompt initiation of a Global Action...
Read more158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage
On 2 February 2026, PATH delivered a joint constituency statement on Agenda itea 6: Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases at the 158th session of the WHO Executive Board. Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the...
Read morePublications
See allThe innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
The role of assessment reports in enabling regulatory reliance – perspectives from the pharmaceutical industry
Reliance in decision-making offers a pathway for national regulatory authorities (NRAs) to consider evaluations conducted by other NRAs while maintaining accountability for their decisions. By avoiding duplicative reviews and optimizing resource allocation, the use of regulatory reliance can lead to faster patient access to safe, effective, and high-quality medical products in a timely manner. A...
Read more
Best practices for unilateral reliance for initial marketing authorization and post-approval changes
Regulatory reliance has emerged as a key strategy for strengthening regulatory systems by optimizing resources, reducing duplication, and accelerating access to high-quality medicines. By leveraging the expertise and prior decisions of trusted national regulatory authorities (NRAs), reliance allows NRAs to focus their efforts on critical public health priorities while maintaining sovereignty over final regulatory decisions....
Read more
Expert insights
See all
A new dawn in global health: UHC as the path toward national health stewardship
Read more
Health as an economic priority – building on momentum driven by the G20 South Africa Presidency
Read more
Getting procurement right: sustainable and secure supply chains that support access to medicines
Read moreResources
See allStreamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more